An open label study to evaluate the effect of first line treatment with Tarceva [erlotinib] in combination with gemcitabine on overall survival and disease progression in patients with locally advanced, unresectable or metastatic pancreatic cancer.

Trial Profile

An open label study to evaluate the effect of first line treatment with Tarceva [erlotinib] in combination with gemcitabine on overall survival and disease progression in patients with locally advanced, unresectable or metastatic pancreatic cancer.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Erlotinib (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 17 Jun 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 09 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top